Previous
Pause
Siguiente
Skip to Navigation
↓
Congresos
Año
Año
Año
-Año
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Investigador
Todos
dgomez
usuario_prueba
Almeida e Silva, Filomena Augusta
Amorín , Ricardo
Angás Pajas, Jorge
Arenal , Raúl
Baptista , Pedro Miguel
Bernechea Navarro, María
Bover Arbós, Pere
Calvo Lacosta, Jorge Hugo
Carstensen , Hans-Heinrich
Castro Barrigón, Alberto
Cazcarro Castellano, Ignacio
Cobarrubias Baglietto, Sebastián Felipe
DeMiguel , Daniel
Espina Cadena, Laura
Fernandez Antoran, David
Ferrio Díaz, Juan Pedro
Gil Hernández, Vanesa
Gracia Lostao, Ana Isabel
Gurauskis , Jonas
Hernández Ainsa, Silvia
Hernández Latas, José Antonio
Hurtado Guerrero, Ramón
Jiménez Schuhmacher, Alberto
Juarez-Perez , Emilio J.
Köhler , Ralf
Martínez-Padilla , Jesús
Millán Gasca, Javier
Montiel , Manuel
Muñoz Soro, José Félix
Olmo , Jose
Ordovás Vidal, Laura
Philippidis , George
Pozo Gonzalo, Cristina
Ramón García, Santiago
Roque , Carla
Schoorlemmer , Jon
Sola , Daniel
Stavridis , Stelios
Sánchez Martínez, Diego
Velasco Lozano, Susana
Íñiguez Dieste, David
Título
Título
Año
REPURPOSING BETA-LACTAMS FOR BURULI ULCER TREATMENT
2018
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic.
2021
Repurposing Beta-lactams for Buruli Ulcer Therapy, from the Bench to the Clinic
2022
Repurposing beta-lactams for Buruli ulcer therapy
2020
Repurposing beta-lactams for Buruli ulcer therapy
2020
Repurposing avermectins for the treatment of infections by non-tuberculous mycobacteria
2020
Régimen con betalactámicos para reducir el tratamiento de la úlcera de Buruli: tratamiento estándar de 8 semanas (rifampicina más claritromicina) versus 4 semanas de tratamiento estándar más amoxicilina/clavulanato [RC8 vs. RCA4] (ensayo clínico BLMs4BU)
2022
Recapitulation of pulmonary SARS-CoV-2 infection in vitro in a novel 3D human lung organoid model with innate immune and stromal cells
2022
Preliminary studies to elucidate the mode of action of a new chemical series with antimicrobial activity
2018
PRELIMINARY STUDIES FOR THE ELUCIDATION OF THE MODE OF ACTION OF THE AVERMECTINS AS ANTI-TB AGENTS
2019
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay
2022
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay
2022
OPTIKA – a new high content drug combination dynamic assay / Hollow-fibre models
2022
Nuevos métodos para la búsqueda de combinaciones sinérgicas
2019
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria
2021
New methodologies to test antibiotic susceptibility against emerging pathogens in cystic fibrosis
2019
Multicentric in-vitro characterization of MPL-204, a new anti- tuberculosis drug candidate, by the ERA4TB collaborative initiative
2022
Mode of action elucidation studies of the avermectins against Mycobacteria
2019
Mode of action elucidation studies of a new chemical series active against Mycobacteria and other microbial pathogens
2019
Mathematical model of meropenem against Mycobacterium tuberculosis
2019
Páginas
« primera
‹ anterior
1
2
3
4
siguiente ›
última »